Filing Overview
Acurx Pharmaceuticals, Inc. filed a Form 8-K dated May 11, 2022, under Item 2.02 to announce financial results for the first quarter ended March 31, 2022, and provide a business update. The filing identifies Exhibit 99.1 as the related press release, but the press release text is not included in the provided filing content.
Financial Results and Liquidity
- The filing text does not provide clear values for revenue, net income or loss, operating expenses, cash flow, cash and cash equivalents, debt, liquidity, or margins.
- The filing text does not provide a clear comparison with the first quarter of the prior year.
Business Update, Outlook, and Risks
The filing states that the company provided a business update in the press release furnished as Exhibit 99.1. Specific development activities, guidance, outlook, risks, contingencies, and unusual items are not described in the supplied filing text.
The Form 8-K and Exhibit 99.1 are furnished rather than filed for purposes of Section 18 of the Exchange Act, except where expressly incorporated by reference.
Key Facts to Verify
- Obtain and review Exhibit 99.1 for the complete first-quarter financial results and business update.
- Verify cash balances, cash burn, operating expenses, and expected funding needs.
- Review any clinical, regulatory, or development milestones and associated timing disclosed in the press release.
- Check for management guidance, going-concern language, financing plans, and material risk updates.
- Confirm year-over-year changes in revenue, net loss, research and development spending, and liquidity.